CRANBURY, N.J.--(BUSINESS WIRE)--OncLive®, a leading digital provider of resources and information to oncology professionals, announces the State of the Science Summit™: Breast Cancer. The event will take place on Oct. 11, at the JW Marriott San Francisco Union Square in San Francisco. The conference will be chaired by Hope S. Rugo, M.D., clinical professor, department of medicine (hematology/oncology), director, breast oncology, clinical trials program, University of California, San Francisco.
This three-and-a-half-hour educational event is designed to discuss some of the most pressing topics in breast cancer, including genomic testing in early- and late-state disease, advanced HER2-positive breast cancer and triple-negative breast cancer. The summit will feature the following prominent medical professionals from University of California, San Francisco (UCSF):
- A. Jo Chien, M.D.
- Melanie Majure, M.D.
- Michelle Melisko, M.D.
- Laura van ‘t Veer, Ph.D.
State of the Science Summit™ is a premier conference series hosted by OncLive® with medical experts from across the nation. Aiming to discuss the current treatment options, the summit integrates academic and community-based physicians and health care professionals across key disciplines that range from medical and surgical oncology and hematology.
To secure a seat and to get more information, please visit www.onclive.com/meetings/soss or contact Allison Cooper at: ACooper@curetoday.com.
About OncLive®
A digital platform of resources for practicing oncologists, OncLive.com offers oncology professionals information they can utilize to help provide the best patient care. OncLive® is the official website for Michael J. Hennessy Associates’ Oncology Specialty Group, which publishes OncologyLive®, Oncology Nursing News®, Oncology Business Management™ and more. Michael J. Hennessy Associates, Inc. is a full-service health care communications company offering education, research, medical media, including curetoday.com and CURE® magazine, the largest U.S. consumer publication focused entirely on cancer. Combining science and humanity to make cancer understandable, CURE® reaches patients, cancer centers and advocacy groups.
